Publications by authors named "Michelle Boyer"

Claim this Profile
R
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.
Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson, Michelle Boyer

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Arnon P Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Michelle Boyer

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Michelle Boyer

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.
Arnon P Kater, Barbara F Eichhorst, Carolyn J Owen, Ulrich Jaeger, Brenda Chyla, Michelle Boyer

Hemasphere· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michelle Boyer

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
John F Seymour, Thomas J Kipps, Barbara F Eichhorst, James D'Rozario, Carolyn J Owen, Michelle Boyer

Blood· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, Lindsey E Roeker, Jeffrey J Pu, Michelle Boyer

Blood Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.
Jeffrey P Sharman, Juliana M L Biondo, Michelle Boyer, Kirsten Fischer, Michael Hallek

EJHaem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink, Michelle Boyer

Lancet Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Anthony R Mato, Jeff P Sharman, Juliana M L Biondo, Mei Wu, Yong Mun, Michelle Boyer

Haematologica· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Michelle Boyer

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy.
Sasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, Matthew S Davids, Shuo Ma, Michelle Boyer

EJHaem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Arnon P Kater, Jenny Qun Wu, Thomas Kipps, Barbara Eichhorst, Peter Hillmen, Michelle Boyer

J Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Rong Deng, Leonid Gibiansky, Tong Lu, Xiaobin Li, Dan Lu, Michelle Boyer

Leuk Lymphoma· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Rong Deng, Leonid Gibiansky, Tong Lu, Priya Agarwal, Hao Ding, Michelle Boyer

Clin Pharmacokinet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Arnon P Kater, John F Seymour, Peter Hillmen, Barbara Eichhorst, Anton W Langerak, Michelle Boyer

J Clin Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Michelle Boyer

N Engl J Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
Fred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Michelle Boyer

Clin Lung Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Heather Wakelee, Zanete Zvirbule, Filippo De Braud, C Daniel Kingsley, Tarek Mekhail, Michelle Boyer

Clin Lung Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Toward pertinent analytical objectives for haematological parameters].
Cristina Iobagiu, Diane Nehar, Isabelle Denis, Aurélie de Saint-Trivier, Michelle Boyer

Ann Biol Clin (Paris)· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged latent schistosomiasis diagnosed 38 years after infestation in a HIV patient.
Barry Payet, Gilles Chaumentin, Michelle Boyer, Paula Amaranto, Claire Lemonon-Meric

Scand J Infect Dis· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caffeine as a performance-enhancing drug in rats: sex, dose, housing, and task considerations.
Michelle Boyer, Stephanie Rees, Joanne Quinn, Karen Grattan-Miscio, Meghan McCallum

Percept Mot Skills· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis